Search Results - "Buttgereit, Thomas"

Refine Results
  1. 1

    The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend by Palmowski, Yannick, Buttgereit, Thomas, Buttgereit, Frank

    Published in Rheumatology (Oxford, England) (01-04-2019)
    “…Abstract Seventy years ago, the first administration of cortisone in a patient with RA marked a milestone in the treatment of inflammatory diseases. However,…”
    Get full text
    Journal Article
  2. 2

    Inhibition of Complex I of the Respiratory Chain, but Not Complex III, Attenuates Degranulation and Cytokine Secretion in Human Skin Mast Cells by Buttgereit, Thomas, Pfeiffenberger, Moritz, Frischbutter, Stefan, Krauß, Pierre-Louis, Chen, Yuling, Maurer, Marcus, Buttgereit, Frank, Gaber, Timo

    “…The mechanisms of mast cell (MC) degranulation and MC-driven skin symptoms are well-described. In contrast, data about the role of mitochondrial respiration…”
    Get full text
    Journal Article
  3. 3

    The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center by Buttgereit, Thomas, Vera Ayala, Carolina, Aykanat, Seda, Weller, Karsten, Gutsche, Annika, Maurer, Marcus, Magerl, Markus

    Published in Frontiers in immunology (2024)
    “…Lanadelumab is a first-line long-term prophylaxis (LTP) in hereditary angioedema (HAE). Real-life data on its long-term efficacy and safety are limited. It is…”
    Get full text
    Journal Article
  4. 4

    Production of IL-6 and Phagocytosis Are the Most Resilient Immune Functions in Metabolically Compromised Human Monocytes by Krauss, Pierre-Louis, Pfeiffenberger, Moritz, Damerau, Alexandra, Buttgereit, Thomas, Chen, Yuling, Gaber, Timo, Buttgereit, Frank

    Published in Frontiers in immunology (19-10-2021)
    “…At sites of inflammation, monocytes carry out specific immune functions while facing challenging metabolic restrictions. Here, we investigated the potential of…”
    Get full text
    Journal Article
  5. 5

    Patient-physician interactions in hereditary angioedema-Key learnings from the coronavirus disease 2019 pandemic by Maurer, Marcus, Buttgereit, Thomas, Magerl, Markus, Schön, Kathrin, Balla, Zsusanna, Farkas, Henriette

    Published in Clinical and translational allergy (01-09-2023)
    “…The coronavirus disease pandemic and its containing measures have caused concerns for patients with hereditary angioedema (HAE) and their treating physicians…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Sensitivity to change and minimal clinically important difference of the angioedema control test by Fijen, Lauré M, Vera, Carolina, Buttgereit, Thomas, Bonnekoh, Hanna, Maurer, Marcus, Magerl, Markus, Weller, Karsten

    Published in Clinical and translational allergy (01-09-2023)
    “…The Angioedema Control Test (AECT) is a patient-reported outcome measure developed and validated for the assessment of disease control in patients with…”
    Get full text
    Journal Article
  8. 8

    Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study by Buttgereit, Thomas, Vera, Carolina, Weller, Karsten, Gutsche, Annika, Grekowitz, Eva Maria, Aykanat, Seda, Wahn, Volker, Krüger, Renate, Maurer, Marcus, Magerl, Markus

    “…Lanadelumab has been available in Germany for the prophylactic treatment of hereditary angioedema since February 2019. To investigate real-life treatment…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Case report: Recurrent angioedema: Diagnosing the rare and the frequent by Buttgereit, Thomas, Fijen, Lauré M, Vera, Carolina, Bergmann, Karl-Christian, Maurer, Marcus, Magerl, Markus

    Published in Frontiers in medicine (02-12-2022)
    “…Hereditary angiodema with normal C1 inhibitor and unknown mutation (HAE-nC1INH-UNK), an exceedingly rare subtype of HAE, appears to be often diagnosed in…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    The 7-day recall period version of the Urticaria Control Test—UCT7 by Buttgereit, Thomas, Salameh, Pascale, Sydorenko, Olga, Zuberbier, Torsten, Metz, Martin, Weller, Karsten, Maurer, Marcus

    Published in Journal of allergy and clinical immunology (01-11-2023)
    “…The Urticaria Control Test (UCT) is a well-established, very easy to use and calculate 4-item patient-reported outcome measure to assess chronic urticaria…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Idiopathic mast cell activation syndrome is more often suspected than diagnosed—A prospective real‐life study by Buttgereit, Thomas, Gu, Sophie, Carneiro‐Leão, Leonor, Gutsche, Annika, Maurer, Marcus, Siebenhaar, Frank

    Published in Allergy (Copenhagen) (01-09-2022)
    “…Background Idiopathic mast cell activation syndrome (MCAS) is characterized by three diagnostic criteria: (1) episodic mast cell (MC)‐driven signs/symptoms of…”
    Get full text
    Journal Article
  18. 18

    How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers by Türk, Murat, Carneiro-Leão, Leonor, Kolkhir, Pavel, Bonnekoh, Hanna, Buttgereit, Thomas, Maurer, Marcus

    “…Omalizumab is an effective treatment for patients with chronic spontaneous urticaria (CSU). In routine clinical practice, physicians often face complex cases…”
    Get full text
    Journal Article
  19. 19
  20. 20